Mailed cancer tests battle: which stool test screens better for colon cancer?
NCT ID NCT06931860
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study compares two mailed stool tests—Cologuard and FIT—for colorectal cancer screening in adults aged 45-49 who are not up to date with screening. Researchers will measure how many people complete screening and follow up on abnormal results. The goal is to find the most effective way to detect colorectal cancer early in this age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cologuard (multi-target stool DNA test) and FIT (fecal immunochemical test)
- What this could lead to
- If this trial succeeds, it could show which mailed stool test works better for screening younger adults, potentially increasing early detection of colorectal cancer.
- What could go wrong
- This is a small, early-stage study (400 participants) comparing two existing tests, not a new treatment. Results may not apply to broader populations or different healthcare settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California San Diego
La Jolla, California, 92093, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- Can a common laxative beat the standard prep for colon cancer screening?
- Phone nudges vs. cancer: can a simple app message save lives?
- Could a simple water trick help more doctors screen for colon cancer?
- New drug combo aims to boost response in Hard-to-Treat colorectal cancer
- First-in-Class cancer drug targets Hard-to-Treat tumors